Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

CTi Biopharma Corp (NASDAQ:CTIC)

0.37
Delayed Data
As of Jun 24
 -0.0326 / -8.10%
Today’s Change
0.25
Today|||52-Week Range
2.23
-69.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$104.7M

Company Description

CTI BioPharma Corp. operates as a biopharmaceutical company, which is focused on the acquisition, development, and commercialization novel targeted therapies covering a spectrum of blood-related cancers. Its products include Pixuvri, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Contact Information

CTI BioPharma Corp.
3101 Western Avenue
Seattle Washington 98121
P:(206) 282-7100
Investor Relations:
(206) 272-4343

Employees

Shareholders

Other institutional24.48%
Individual stakeholders18.36%
Mutual fund holders14.57%

Top Executives

James A. BiancoPresident, Chief Executive Officer & Director
Lou A. BiancoSecretary, Executive VP-Finance & Administration
Jack W. SingerDirector, Chief Scientific & Medical Officer
Matthew J. PlunkettChief Business Officer & Executive Vice President
Bruce J. SeeleyChief Commercial Officer & Executive VP